Serum STREM and MNDA Mointoring in ICU

Completed

• Conditions: Sepsis .

• Registration Number: NCT02120521
• Lead Sponsor: Tanta University

Brief Summary

A total of 120 patients will be included in the study. Sixty patients are critically ill with evidence of sepsis during ICU stay (sepsis group) and sixty patients are critically ill without evidence of infectious organism (SIRS group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of sTREM-1 and MNDA will be monitored.

Detailed Description

A total of 120 patients will be included in the study. Sixty patients are critically ill with evidence of sepsis during ICU stay (sepsis group) and sixty patients are critically ill without evidence of infectious organism (SIRS group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of sTREM-1 and MNDA will be monitored.

At admission, patient's age, sex, weight and height were Patients data that include the clinical status; sequential organ failure assessment (SOFA) score; temperature; heart rate; respiratory rate; blood pressure; central venous pressure; laboratory analysis (complete blood count, blood urea nitrogen, blood sugar, serum sodium, potassium, calcium, aspartate aminotransferase, alanine aminotransferase, prothrombin time, albumin and CRP) and arterial blood gas analysis were measured. Routine cultures of suspected sites, blood and urine were obtained to determine the presence of infection. We attempted to maintain the patient hemoglobin level at 10-12g/dl and central venous pressure at 8-12 cmH2o. When needed, intravascular fluid replacement, blood products and inotropic or vasopressor agents were administered. Each day the attending physician evaluated all the study patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU.

The signs of sepsis were body temperature \<36C° or \> 38C°, tachycardia (\>90 beats/min), ventilatory frequency\>20 breath/min or Pco2\<32mmHg (unless the patient was mechanically ventilated), a white cell count ≥12×109 litre-1 or \< 4x 109 litre-1, or \>10% immature neutrophils, in addition to the presence of infection. Severe sepsis is a sepsis associated with evidence of organ dysfunction , hypoperfusion, acute alteration of mental status, elevated plasma lactate, unexplained metabolic acidosis (arterial ph\<7.3), hypoxaemia, prolonged prothrombin time or decrease in platelet count \>50% or ≤100×109litre1, oliguria and hypotension defined as systolic arterial pressure \<90mmHg or a decrease of \>40mmHg. Septic shock was defined as hypotension (\<90/60mmHg) in addition to sepsis syndrome persisting despite adequate fluid resuscitation and requiring intropic support

Study Timeline

• Study Start: 2013-04
• Primary Completion: 2014-04
• Study First Submitted: 2014-04-18
• Study First Submitted QC: 2014-04-18
• Study First Posted: 2014-04-22
• Study Completion: 2014-05
• Status Verified: 2014-12
• Last Update Submitted: 2014-12-14
• Last Update Posted: 2014-12-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• The patients staying in ICU for more than 24 hours will be included in the study.

Exclusion Criteria

• Patients received anti-inflammatory drugs or corticosteroids before admission, patients had immunosuppressive illness, patients had chronic organ failure; patients received massive blood transfusion; patients with radiation therapy and patients with previous organ transplantation will be excluded from the study.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
dynamic changes of serum sTREM-1 and MNDA	one week	determine the dynamic changes of serum sTREM-1 and the corresponding changes of serum MNDA and their correlation in critically ill sepsis and SIRS patients.

Secondary Outcome Measures

Name	Time	Method
Survival in critically ill sepsis and SIRS patients	two weeks	determine the dynamic changes of serum sTREM-1 and the corresponding changes of serum MNDA and their correlation in critically ill sepsis and SIRS patients and survival .

Trial Locations

Locations (1)

Tanta University hospitals; 🇪🇬 Tanta, Algharbyia, Egypt